Voyager Therapeutics (VYGR) Baird's 2024 Global Healthcare Conference summary

Partnership and collaboration updates

• Expanded collaboration with Novartis, adding a fifth partnered program and $15 million in new funding, with potential for additional milestones.

• Total of 14 partnered programs across the TRACER capsid technology, including both active and passive collaborations.

• Neurocrine partnership includes seven programs, with Friedreich's ataxia and GBA1 Parkinson's disease advancing toward INDs in 2025.

• Over $400 million raised through business development transactions, with $8.2 billion in potential milestones across partnerships.

• Partnerships structured to allow for milestone payments, royalties, and opt-in rights for co-promotion on select programs.

Financial position and runway

• Cash position of $371 million as of last quarter, providing runway into 2027.

• Potential milestone payments from partnerships are not included in the current cash runway, offering further extension.

• Active collaborations reimburse internal FTEs, supporting internal pipeline advancement.

Scientific and pipeline progress

• Three gene therapy programs, including the wholly owned SOD1-ALS, are set to enter the clinic next year, using next-generation TRACER capsids.

• SOD1-ALS program aims for IND filing in the second half of next year, with initial clinical readouts expected soon after.

• TRACER capsids engineered for improved CNS delivery, cross-species activity, and reduced off-target effects, especially in the liver.

• Lower doses enabled by TRACER capsids reduce cost of goods and improve safety.